Multivalent antiviral conjugates enhance activity against Influenza via cross-linking viruses
In the authors' words
Abstract Long-acting drug–Fc conjugate (CD388) has emerged as a new class of antivirals against influenza A and B, yet the mechanisms governing how Fc conjugation reshapes small-molecule function remain undefined. Here we establish a programmable multivalent antiviral conjugates (AVCs) platform by click chemistry that enables flexible combination of valencies and conjugated drugs, allowing systematic interrogation of valency-dependent antiviral mechanisms. Using zanamivir as a model, mono-, di-, and trivalent zanamivir are conjugated with Fc, with trivalent zanamivir-Fc conjugates (AVC-Z3) exhibiting higher activity than lower-valent AVCs. AVC-Z3 induces inter-virion aggregation, thereby coupling blockade of viral entry with restriction of viral release. This cross-linking–mediated dual-stage inhibition represents a mechanistic shift from neuraminidase suppression to physical viral immobilization. Furthermore, trivalent peramivir-Fc conjugate (AVC-P3) is synthesised and exhibits stronger antiviral activity than AVC-Z3 in vitro, with much longer half-life in vivo than AVC-Z3, and CD388 with YTE mutation. The in vivo antivirus efficacy of AVC-P3 surpasses other AVCs, baloxavir, and CD388 in H1N1-, H3N2-, H5N1-, and influenza B-infection mice models. Together, our findings define ligand valency as a determinant of antiviral mechanism.
In plain words AI summary
The researchers built a flexible platform to create antiviral drugs with different numbers of attached drug molecules. They found that a version with three zanamivir molecules worked better than versions with one or two. This triple version clumps viruses together, blocking both entry into cells and release from them. A similar triple version using peramivir lasted longer in the body and worked better than other drugs in mice infected with four different flu strains. The authors conclude that the number of drug molecules attached determines how the antiviral works.
Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source.
Appeared: Tuesday, October 6. Nature Communications. Peer-reviewed journal.